IP Library › Granted Patent US 12,186,343
Granted Patent B2
US 12,186,343 · App. 16/979,102 · Granted Jan 7, 2025

Method and composition for treating tumors

Inventors: Zonghai Li (Shanghai, CN); Huamao Wang (Shanghai, CN); Min Zhou (Shanghai, CN)
Assignee: CRAGE MEDICAL CO., LIMITED
A61K35/17A61K31/337A61K31/675A61K31/7076A61K38/1774A61K47/643A61P35/00A61K39/4611A61K39/4631A61K2039/545A61K2239/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,343
App. No.
16/979,102
Granted
Jan 7, 2025
Kind
B2
Abstract

Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.

Claims (25)

1. A method for treating a CLD18A2-positive tumor, comprising administering a first dose of immune effector cells to a subject in need thereof, wherein the immune effector cells express a chimeric antigen receptor (CAR) that specifically recognizes CLD18A2, wherein the method further comprises a pretreatment performed before administering the first dose of the immune effector cells, and the pretreatment comprises administering a chemotherapeutic agent to the subject, and wherein the chemotherapeutic agent comprises cyclophosphamide, fludarabine, and albumin-bound paclitaxel, and wherein the pretreatment is performed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days before the first dose of the immune effector cells is administered.

2. The method of claim 1 , wherein the first dose contains a total amount of the immune effector cells not more than 2×10 9 cells.

3. The method of claim 1 , wherein after the first dose of the immune effector cells is administered, at least one subsequent dose of immune effector cells expressing a chimeric antigen receptor (CAR) that specifically recognizing CLD18A2 is administered.

4. The method of claim 3 , wherein the at least one subsequent dose contains a total amount of the immune effector cells not more than 2×10 9 cells.

5. The method of claim 1 , wherein the pretreatment is performed days before the first dose of the immune effector cells is administered.

6. The method of claim 1 , wherein the tumor is breast cancer, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, lung cancer, gastric cancer, small bowel cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, ovarian cancer, anal cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, bladder cancer, kidney cancer, ureter cancer, renal pelvis cancer, central nervous system (CNS) tumor, primary CNS lymphoma, spinal tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, or squamous cell carcinoma.

7. The method of claim 1 , wherein the chimeric antigen receptor comprises an scFv antibody fragment specifically binding to CLD18A2, a transmembrane domain, and an intracellular domain, and wherein the scFv antibody fragment comprises:

HCDR1 as shown in SEQ ID NO:1; HCDR2 as shown in SEQ ID NO:2; HCDR3 as shown in SEQ ID NO:3; LCDR1 as shown in SEQ ID NO:4; LCDR2 as shown in SEQ ID NO: 5; and LCDR3 as shown in SEQ ID NO: 6; or

HCDR1 as shown in SEQ ID NO:1; HCDR2 as shown in SEQ ID NO:7; HCDR3 as shown in SEQ ID NO:3; LCDR1 as shown in SEQ ID NO:4; LCDR2 as shown in SEQ ID NO: 5; and LCDR3 as shown in SEQ ID NO: 6; or

HCDR1 as shown in SEQ ID NO: 8; HCDR2 as shown in SEQ ID NO:9 or 68; HCDR3 as shown in SEQ ID NO: 10; LCDR1 as shown in SEQ ID NO:11; LCDR2 as shown in SEQ ID NO: 12; and LCDR3 as shown in SEQ ID NO: 13.

8. The method of claim 7 , wherein the scFv antibody fragment comprises a heavy chain variable region as shown in SEQ ID NO: 14 and a light chain variable region as shown in SEQ ID NO: 16; or a heavy chain variable region as shown in SEQ ID NO: 18 and a light chain variable region as shown in SEQ ID NO: 16; or a heavy chain variable region as shown in SEQ ID NO: 22 and a light chain variable region as shown in SEQ ID NO: 20; or a heavy chain variable region as shown in SEQ ID NO:53 and a light chain variable region as shown in SEQ ID NO:52.

9. The method of claim 7 , wherein the scFv antibody fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 54, 56, 57 and 58.

10. The method of claim 7 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, 27, 28, 29, 30, 31, and 32.

11. The method of claim 1 , wherein the immune effector cells are T lymphocytes, NK cells, or NKT lymphocytes.

12. The method of claim 1 , wherein the chemotherapeutic agent is administered daily for 2, 3, 4, 5, 6, or 7 days.

13. The method of claim 12 , wherein the cyclophosphamide and the fludarabine are administered daily for 2, 3, or 4 days, and the albumin-bound paclitaxel is administered once; or the cyclophosphamide, the fludarabine, and the albumin-bound paclitaxel are administered daily for 2, 3, or 4 days.

14. The method of claim 1 , wherein the tumor is a digestive tract tumor.

15. The method of claim 14 , wherein the digestive tract tumor is adenocarcinoma.

16. The method of claim 1 , wherein the tumor is pancreatic cancer, gastric cancer, gastric adenocarcinoma, esophageal cancer, rectal cancer, anal cancer, or small bowel cancer.

17. The method of claim 1 , wherein the fludarabine is administered at about 10-50 mg/m 2 /day, or about 15-40 mg/m 2 /day, or about 15-30 mg/m 2 /day, or about 20-30 mg/m 2 /day, or about 25 mg/m 2 /day; and

the cyclophosphamide is administered at about 300-700 mg/m 2 /day, or about 400-650 mg/m 2 /day, or about 450-600 mg/m 2 /day, or about 450-550 mg/m 2 /day, or about 490-550 mg/m 2 /day, or about 250 mg/m 2 /day; and

the albumin-bound paclitaxel is administered at not higher than about 300 mg/m 2 /day, or not higher than about 200 mg/m 2 /day, or not higher than about 150 mg/m 2 /day, or not higher than about 100 mg/m 2 /day, or not higher than about 80 mg/m 2 /day, or not higher than about 70, 69, 68, 67, 66, 65, 64, 63, 62, or 61 mg/m 2 /day, or the albumin-bound paclitaxel is administered at 100 mg/m 2 /day.

18. The method of claim 17 , wherein the fludarabine is administered at about 25 mg/m 2 /day for 2 days, the cyclophosphamide is administered at about 250 mg/m 2 /day for 3 days, and the albumin-bound paclitaxel is administered at 100 mg/m 2 /day or for one day.

19. The method of claim 1 , wherein the chimeric antigen receptor comprises at least two or three intracellular signaling domains.

20. The method of claim 19 , wherein the at least two or three intracellular signaling domains are selected from the group consisting of a signaling domain of TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CDS, CD22, CD79a, CD79b, CD66d, CD28, CD137, OX40, DAP10, and ICOS.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: CAFA THERAPEUTICS LIMITED
To: CRAGE MEDICAL CO., LIMITED
Reel/Frame 059227/0425 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: CARSGEN THERAPEUTICS CO., LTD.; SHANGHAI CANCER INSTITUTE
To: CAFA THERAPEUTICS LIMITED
Reel/Frame 056905/0388 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: LI, ZONGHAI; WANG, HUAMAO; ZHOU, MIN
To: CARSGEN THERAPEUTICS CO., LTD.; SHANGHAI CANCER INSTITUTE
Reel/Frame 056909/0220 →
Priority Claims (4)
CN 201810196524.0 · Mar 9, 2018 · national
CN 201810806560.4 · Jul 20, 2018 · national
CN 201811039594.1 · Sep 6, 2018 · national
CN 201811495012.0 · Dec 7, 2018 · national
Continuity (1)
Related Publication 20220110973A1 · Apr 14, 2022
References Cited (141)
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 7446190B2 · Sadelain et al. · 2008 [cited by applicant]
US 9175308B2 · Shiku et al. · 2015 [cited by applicant]
US 10377822B2 · Wang et al. · 2019 [cited by applicant]
US 11111295B2 · Wang · 2021 [cited by examiner]
US 11198729B2 · Wang et al. · 2021 [cited by applicant]
US 20070186437A1 · Gasteyer et al. · 2007 [cited by applicant]
US 20160206656A1 · Gilbert · 2016 [cited by examiner]
US 20170204177A1 · Wang et al. · 2017 [cited by applicant]
CN 103483453A · 2014 [cited by applicant]
CN 103820393A · 2014 [cited by applicant]
CN 105194661A · 2015 [cited by applicant]
CN 105315375A · 2016 [cited by applicant]
CN 105331585A · 2016 [cited by applicant]
CN 105713881A · 2016 [cited by applicant]
CN 106146666A · 2016 [cited by applicant]
CN 106397593A · 2017 [cited by applicant]
CN 106467573A · 2017 [cited by applicant]
CN 106519037A · 2017 [cited by applicant]
CN 106554414A · 2017 [cited by applicant]
CN 107058354A · 2017 [cited by applicant]
CN 107106610A · 2017 [cited by applicant]
CN 107460201A · 2017 [cited by applicant]
CN 107893052A · 2018 [cited by applicant]
JP 2006502117A · 2006 [cited by applicant]
JP 2009517354A · 2009 [cited by applicant]
JP 2017522024A · 2017 [cited by applicant]
JP 2017533904A · 2017 [cited by applicant]
WO WO8909622A1 · 1989 [cited by applicant]
WO WO9007861A1 · 1990 [cited by applicant]
WO WO9110741A1 · 1991 [cited by applicant]
WO WO9208796A1 · 1992 [cited by applicant]
WO WO9402602A1 · 1994 [cited by applicant]
WO WO9428143A1 · 1994 [cited by applicant]
WO WO9633735A1 · 1996 [cited by applicant]
WO WO2005113587A2 · 2005 [cited by applicant]
WO WO2007059997A1 · 2007 [cited by applicant]
WO WO2012038055A1 · 2012 [cited by applicant]
WO WO2013051718A1 · 2013 [cited by applicant]
WO WO2014055668A1 · 2014 [cited by applicant]
WO WO2014075788A1 · 2014 [cited by applicant]
WO WO2014180306A1 · 2014 [cited by applicant]
WO WO2015113576A1 · 2015 [cited by applicant]
WO WO2016008405A1 · 2016 [cited by applicant]
WO WO2015172339A8 · 2016 [cited by applicant]
WO WO2016064929A1 · 2016 [cited by applicant]
WO WO2016160621A2 · 2016 [cited by applicant]
WO WO2016180468A1 · 2016 [cited by examiner]
WO WO2016180782A1 · 2016 [cited by examiner]
WO WO2016191756A1 · 2016 [cited by examiner]
WO 2017165571A1 · 2017 [cited by applicant]
WO WO2017186121A1 · 2017 [cited by examiner]
WO WO2018006882A1 · 2018 [cited by examiner]
WO WO2019047932A1 · 2019 [cited by examiner]
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295. [cited by examiner]
Rudikoff et al, Proc. Natl. Acad. Sci. USA, 1982, 79(6):1979-1983. [cited by examiner]
Colman, Research in Immunology, 1994, 145:33-36. [cited by examiner]
Bendig, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93. [cited by examiner]
Khantasup et al., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34(6): 404-417. [cited by examiner]
Murphy et al., Journal of Immunological Methods, vol. 463, p. 127-133, 2018. [cited by examiner]
English Translation of the International Search Report mailed Jun. 17, 2019 corresponding to PCT/CN2019/077529 filed Mar. 8, 2019; 4 pages. [cited by applicant]
Alonso-Camino et al.: CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol. Ther. Nucleic Acids. 2(5):e93 (2013). [cited by applicant]
Beatty et al. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology 3(11):e970027 (2014). [cited by applicant]
Brash, Douglas E et al. Strontium Phosphate Transfection of Human Cells in Primary Culture: Stable Expression of the Simian Virus 40 Large-t-antigen Gene in Primary Human Bronchial Epithelial Cells. Molecular and Cellul… [cited by applicant]
Brentjens, et al. CAR T Update Part 2: Challenges and Opportunities in Solid Tumors. Published by the Memorial Sloan Kettering Cancer Center, New York, NY. at https://www.mskcc.org/clinical-updates/car-update-part-2-cha… [cited by applicant]
Brown, Christine, et al., Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. The New England Journal of Medicine 375(26):2561-9 (2016). [cited by applicant]
Carlens et al.: Ex vivo T lymphoccyte expansion for retroviral transduction: Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. Exp. Hematol. 28(10):1137-1146 (2000). [cited by applicant]
Carpenito et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. PNAS USA 106(9):3360-3365 (2009). [cited by applicant]
Cartellieri, et al., Chimeric antigen receptor-engineered T cells for immunotherapy of Cancer, J Biomed Biotechnol, 2010, 1-10. Doi : 10.1155/2010/956304. [cited by applicant]
Casucci, Monica, et al., Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunology 64(1):123-30 (2015). [cited by applicant]
Cavaletti, Guido, et al., Chemotherapy-induced Peripheral Neurotoxicity. Nature Reviews. Neurology 6(12):657-666 (2010). [cited by applicant]
Cavalieri, et al., Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102(2):497-505 (2003). [cited by applicant]
Chicaybam, Leonardo, et al., An Efficient Low Cost Method for Gene Transfer to T Lymphocytes. PloS one 8(3):e60298 (2013). [cited by applicant]
Citation in opposition procedure—D1—WO2015/113576 A1 + sequence listing. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Oppo… [cited by applicant]
Citation in opposition procedure—D10—English machine translation of D6. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Oppos… [cited by applicant]
Citation in opposition procedure—D11—Sadelain et al. 2013, Cancer Discovery 3: 388-398. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated Lis… [cited by applicant]
Citation in opposition procedure—D12—EP3170842 (opposed patent). Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Opposition D… [cited by applicant]
Citation in opposition procedure—D13—English-language translation of the application as filed PCT/CN2015/084023 (published in Chinese as WO 2016/008405), as filed by the Patentee at the European Patent Office on Jan. 30… [cited by applicant]
Citation in opposition procedure—D14—CN201410341504. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Opposition Documents ref… [cited by applicant]
Citation in opposition procedure—D15—WO 2016/180782 A1 + sequence listing. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Op… [cited by applicant]
Citation in opposition procedure—D16—WO 2016/180468 (priority document of D10). Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cit… [cited by applicant]
Citation in opposition procedure—D17—EP3294333, publication of regional phase of D10. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List … [cited by applicant]
Citation in opposition procedure—D18—Annex to D10 showing a sequence alignment between SEQ ID No. 6 and SEQ ID No. 41 of D10. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Applic… [cited by applicant]
Citation in opposition procedure—D19—Annex to D10 showing the NCBI reference sequence for human CD28. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Co… [cited by applicant]
Citation in opposition procedure—D2—Annex to D3 showing a a sequence alignment of SEQ ID No. 6 with SEQ ID Nos. 2-4 of D3. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Applicati… [cited by applicant]
Citation in opposition procedure—D20—Annex to D10 showing the NCBI reference sequence for human CD3£. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Co… [cited by applicant]
Citation in opposition procedure—D3—EP3099706, publication of regional phase of D3. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of… [cited by applicant]
Citation in opposition procedure—D4—EP2765193 (WO2013/051718). Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Opposition Doc… [cited by applicant]
Citation in opposition procedure—D5—WO2014/075788A1 + sequence listing. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Oppos… [cited by applicant]
Citation in opposition procedure—D6—Annex to D5 showing a sequence alignment of SEQ ID No. 6 with SEQ ID Nos. 8, 15 and 46 of D5. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Ap… [cited by applicant]
Citation in opposition procedure—D7—Annex to D5 showing a sequence alignment of SEQ ID No. 6 with SEQ ID No. 38 of D5. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application N… [cited by applicant]
Citation in opposition procedure—D8—Annex to D5 showing a sequence alignment of SEQ ID No. 4 with SEQ ID Nos. 6, 11 and 46 of D5. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Ap… [cited by applicant]
Citation in opposition procedure—D9—CN103483453, cited in the ISR as D3. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Oppo… [cited by applicant]
Citation in opposition procedure—Exhibit A—Alignment SEQ ID_19 with eGFP+SEQID 4. Amino acid sequences contributing to the extracellular binding region of SEQ ID No. 19-22. Opposition by BioNTech Cell & Gene Therapies G… [cited by applicant]
Citation in opposition procedure—Exhibit B—Alignment SEQ ID_20 with eGFP+SEQID 4. Amino acid sequences contributing to the extracellular binding region of SEQ ID No. 19-22. Opposition by BioNTech Cell & Gene Therapies G… [cited by applicant]
Citation in opposition procedure—Exhibit C—Alignment SEQ ID_21 with eGFP+SEQID 6. Amino acid sequences contributing to the extracellular binding region of SEQ ID No. 19-22. Opposition by BioNTech Cell & Gene Therapies G… [cited by applicant]
Citation in opposition procedure—Exhibit D—Alignment SEQ ID_22 with eGFP+SEQID 6. Amino acid sequences contributing to the extracellular binding region of SEQ ID No. 19-22. Opposition by BioNTech Cell & Gene Therapies G… [cited by applicant]
Consolidated list of cited opposition documents. Opposition by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 against EP3170842 Application No. 15821331.4. Consolidated List of Cited Opposition Documents referen… [cited by applicant]
Cooper, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. Feb. 15, 2003;101(4):1637-44. Epub Oct. 10, 2002. [cited by applicant]
Davies, et al. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res, 2010, 70(10):3915-24. [cited by applicant]
Grupp, et al., Adoptive cellular therapy, Curr Top Microbiol Immunol., 2011, 344:149-172. [cited by applicant]
Harmsen et al. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77:13-22 (2007). [cited by applicant]
Hermans et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. Journal of Immunological Methods 285 (2004) 25-40. [cited by applicant]
Huang, Xin, et al., DNA Transposons for Modification of Human Primary T Lymphocytes. Methods in Molecular Biology 506:115-126 (2009). [cited by applicant]
International search report and written opinion dated Jan. 21, 2016 for PCT/CN2015/084023. [cited by applicant]
Johnston SA, et al. Biolistic Transformation: Microbes to Mice. Nature vol. 346,6286: pp. 776-777 (1990). [cited by applicant]
Kim, et al. Enhancement of LFA-1-Mediated T Cell Adhesion by Human T Lymphotropic Virus Type 1 p12. Journal of Immunology, 176(9):5463-70. Year: 2006. [cited by applicant]
Klebanoff et al. Sorting through subsets: Which T cell poulations mediate highly effective adoptive immunotherapy? J Immunother 35(9):651-660 (2012). [cited by applicant]
Kochenderfer et al.: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. Journal of Immunotherapy 32:689-702 (2009). [cited by applicant]
Koste L., et al., T-cell Receptor Transfer Into Human T Cells With Ecotropic Retroviral Vectors. Gene Theraphy 21(5):533-538 (2014). [cited by applicant]
Lupton, Stephen D, et al., Dominant Positive and Negative Selection Using a Hygromycin Phosphotransferase-Thymidine Kinase Fusion Gene. Molecular and Cellular Biology 11(6):3374-3378 (1991). [cited by applicant]
Ma, et al. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019; 15(12): 2548-2560. Published online Sep. 7, 2019. doi: 10.7150/ijbs.34213. [cited by applicant]
Manuri, Pallavi V. et al.: piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. Hum Gene Ther. 21(4):427-437 (2010). doi: 10.1089/hum.2009.114. [cited by applicant]
Morgan, R.A., et al., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, Apr. 18, 2010. pp. 843-851 vol. 18, … [cited by applicant]
Mullen et al.: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 89(1): 33-37 (1992). [cited by applicant]
Nakazawa, Y. Gene-modified T-cell Therapy Using Chimeric Antigen Receptor. The Shinshu Medical Journal. 2013. vol. 61. Issue 4. pp. 197-203, Released Sep. 25, 2013. https://doi.org/10.11441/shinshumedj.61.197. [cited by applicant]
Ngo, et al., Ex vivo gene transfer for improved adoptive immunotherapy of cancer Human Molecular Genetics, 2011, 20(1): R93-99. [cited by applicant]
Notice of opposition dated Jun. 9, 2020 against EP3170842 Application No. 15821331.4 by BioNTech Cell & Gene Therapies GmbH filed Jun. 4, 2020 with non patent literature (D7) Sadelain at al., “The Basic Principles of Ch… [cited by applicant]
Park et al., Treating cancer with genetically engineered T cells. Trends Biotechnol., 29(11):550-557 (2011). [cited by applicant]
Remington: The Science and Practice of Pharmacy. 21st Edition, Lippincott Williams & Wilkins: 4 Pages (2005). [cited by applicant]
Riddell S R, et al., Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified Cd8+ Hiv-specific T Cells for Hiv Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. The Fred Hutchinson … [cited by applicant]
Sadelain et al. The basic principles of chimeric antigen receptor design. Cancer Discov. 3(4):388-98 (2013). [cited by applicant]
Sahin, et al. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Human Cancer Biology. vol. 14. No. 23. pp. 2-13. Dec. 1, 2008. [cited by applicant]
Savoldo, et al., CD28 costimulation improves expansion and persistence of chimeric antigen receptor modified T cells in lymphoma patients, J Clin Invest, May 2011, 121 (5):1822-1826. [cited by applicant]
Sharma, Nynne, et al., Efficient Sleeping Beauty DNA Transposition From DNA Minicircles. Molecular Therapy. Nucleic Acids 2(2):e74 (2013). [cited by applicant]
Stoter, et al., Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J. Clin. Oncol, 2006, 24(13): e20-e22. [cited by applicant]
Swartz, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. May 15, 2012;72(10):2473-80. doi: 10.1158/0008-5472.CAN-12-0122. Epub Mar. 13, 2012. [cited by applicant]
Tendeloo, Van et al., High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery, Gene Therapy vol. 7, pp. 1431-1437; Published: Aug. 21, … [cited by applicant]
Terakura et al., Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119:72-82 (2012). [cited by applicant]
U.S. Appl. No. 15/326,974 Notice of allowance dated Apr. 12, 2019. [cited by applicant]
U.S. Appl. No. 16/448,053 Notice of Allowance dated Sep. 13, 2021. [cited by applicant]
U.S. Appl. No. 16/448,053 Office action dated Jan. 6, 2021. [cited by applicant]
U.S. Appl. No. 15/326,974 Office action dated Jan. 30, 2019. [cited by applicant]
U.S. Appl. No. 16/448,053 Office action dated Aug. 5, 2021. [cited by applicant]
U.S. Appl. No. 15/326,974 Office action dated Sep. 20, 2018. [cited by applicant]
U.S. Appl. No. 17/522,284 Notice of Allowance dated Jun. 5, 2024. [cited by applicant]
U.S. Appl. No. 17/522,284 Office Action dated Feb. 14, 2024. [cited by applicant]
Verhoeyen et al., Lentiviral Vector Gene Transfer into Human T Cells, Methods in Molecular Biology, Methods and Protocols 506:97-114, 2009. [cited by applicant]
Wang et al.: Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. J. Immunother. 35(9):689-701 (2012). [cited by applicant]
Wigler, Michael et al. Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell 11(1):223-232 (1977). [cited by applicant]
Zhang, et al., Chimeric NKG2D-modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways, Can Res 2007, 67 (22): 11029-11036. [cited by applicant]